Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our FC fusion protein technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. Evive's Ryzneuta (G-CSF and IgG2 FC fusion protein, aka F-627) has recently been approved in China, US and EU for treating cancer drug induced neutropenia. In the pipeline, F-652 (IL-22 and IgG2 FC fusion protein) has completed phase I-II clinical studies in acute on chronic liver failure, alcoholic hepatitis, and acute graft vs host disease, and shown good safety, efficacy and PK/PD profiles.